CoChat

AT-MSCs Antifibrotic Activity is Improved by Eugenol through Modulation of TGF-β/Smad Signaling Pathway in Rats

Open access
Fathy, Moustafa, Okabe, Motonori, Saad Eldien, Heba M., Yoshida, Toshiko · 2020 · Molecules

The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.

Abstract

For hepatic failure, stem cell transplantation has been chosen as an alternative therapy, especially for mesenchymal stem cells (MSCs). The aim of this study was to investigate the effect of eugenol (EUG) on the in vivo antifibrotic activity of adipose tissue-derived MSCs (AT-MSCs) and the underlying mechanism. After characterization of MSCs, rats were divided into five groups, Group 1 (normal control), Group 2 (CCl4), Group 3 (CCl4 + AT-MSCs), Group 4 (CCl4 + EUG) and Group 5 (CCl4 + AT-MSCs + EUG). Biochemical and histopathological investigations were performed. Furthermore, expression of type 1 collagen, α-SMA, TGF-β1, Smad3 and P-Smad3 was estimated. Compared to the single treatment with AT-MSCs, the combination treatment of the fibrotic rats with AT-MSCs and EUG significantly improved the plasma fibrinogen concentration, IL-10 level and proliferating cell nuclear antigen expression, and also significantly decreased the serum levels of liver enzymes, IL-6, IL-1β, TNF-α, type III collagen, hyaluronic acid, hydroxyproline and the TGF-β growth factor. Furthermore, the combination treatment significantly decreased the hepatic expression of fibrotic markers genes (Type 1 collagen and α-SMA) and proteins (α-SMA, TGF-β1 and phospho-Smad3) more than the treatment with AT-MSCs alone. We demonstrated that the combination treatment with EUG and AT-MSCs strongly inhibited the advancement of CCl4-induced hepatic fibrosis, compared with AT-MSCs alone, through TGF-β/Smad pathway inhibition. This approach is completely novel, so more investigations are necessary to improve our perception of the underlying molecular mechanisms accountable for the effects of EUG on the antifibrotic potential of AT-MSCs.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/molecules25020348

Cites

31 of 31 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Cell surface markers expression of adipose tissue-derived mesenchymal stem cells (AT-MSCs). Representative histograms of the flow cytometric analysis of the isolated AT-MSCs for the expression of mesenchymal stem cells (MSCs) markers (CD90, CD105 and CD73) and hematopoietic markers (CD34 and CD45). AT-MSCs: Adipose tissue-derived mesenchymal stem cells.
Figure 1 Cell surface markers expression of adipose tissue-derived mesenchymal stem cells (AT-MSCs). Representative histograms of the flow cytometric analysis of the isolated AT-MSCs for the expression of mesenchymal stem cells (MSCs) markers (CD90, CD105 and CD73) and hematopoietic markers (CD34 and CD45). AT-MSCs: Adipose tissue-derived mesenchymal stem cells.CC BY · PubMed Central
Figure 2 Prothrombin time, fibrinogen concentration and liver enzymes levels. (A) Prothrombin time (sec) and plasma fibrinogen concentration (mg/dL) for the different groups. (B) Serum liver enzymes (ALT and AST) levels (U/L) for the different groups. Bars represent mean ± standard deviation (SD). Significant difference between groups is analyzed by one-way analysis of variance (ANOVA) test, where: *; p < 0.05, **; p < 0.01, ***; p < 0.001. AT-MSCs: Adipose tissue-derived mesenchymal stem cells, EUG: Eugenol.
Figure 2 Prothrombin time, fibrinogen concentration and liver enzymes levels. (A) Prothrombin time (sec) and plasma fibrinogen concentration (mg/dL) for the different groups. (B) Serum liver enzymes (ALT and AST) levels (U/L) for the different groups. Bars represent mean ± standard deviation (SD). Significant difference between groups is analyzed by one-way analysis of variance (ANOVA) test, where: *; p < 0.05, **; p < 0.01, ***; p < 0.001. AT-MSCs: Adipose tissue-derived mesenchymal stem cells, EUG: Eugenol.CC BY · PubMed Central
Figure 3 Serum inflammatory cytokines and growth factors levels. (A) Serum cytokines (IL-1β, TNF-α, IL-6 and IL-10) levels (pg/mL) for the different groups. (B) Serum growth factors (HGF and TGF-β) levels (pg/mL) for the different groups. Bars represent mean ± SD. Significant difference between groups is analyzed by one-way ANOVA test, where: *; p < 0.05, **; p < 0.01, ***; p < 0.001. AT-MSCs: Adipose tissue-derived mesenchymal stem cells, EUG: Eugenol, IL-1β: Interlukin-1β; IL-6: Interlukin-6; IL-10: Interlukin-10; TNF-α: Tumor necrosis factor-α; HGF: Hepatocyte growth factor; TGF-β: transforming growth factor-β.
Figure 3 Serum inflammatory cytokines and growth factors levels. (A) Serum cytokines (IL-1β, TNF-α, IL-6 and IL-10) levels (pg/mL) for the different groups. (B) Serum growth factors (HGF and TGF-β) levels (pg/mL) for the different groups. Bars represent mean ± SD. Significant difference between groups is analyzed by one-way ANOVA test, where: *; p < 0.05, **; p < 0.01, ***; p < 0.001. AT-MSCs: Adipose tissue-derived mesenchymal stem cells, EUG: Eugenol, IL-1β: Interlukin-1β; IL-6: Interlukin-6; IL-10: Interlukin-10; TNF-α: Tumor necrosis factor-α; HGF: Hepatocyte growth factor; TGF-β: transforming growth factor-β.CC BY · PubMed Central
Figure 4 Levels of type III collagen, hyaluronic acid and hepatic hydroxyproline content. Serum levels of (A) collagen III and (B) hyaluronic acid (µg/L) for the different groups. (C) Hepatic hydroxyproline content (µg/g liver protein) for the different groups. Bars represent mean ± SD. Significant difference between groups is analyzed by one-way ANOVA test, where: **; p < 0.01, ***; p < 0.001. AT-MSCs: Adipose tissue-derived mesenchymal stem cells, EUG: Eugenol.
Figure 4 Levels of type III collagen, hyaluronic acid and hepatic hydroxyproline content. Serum levels of (A) collagen III and (B) hyaluronic acid (µg/L) for the different groups. (C) Hepatic hydroxyproline content (µg/g liver protein) for the different groups. Bars represent mean ± SD. Significant difference between groups is analyzed by one-way ANOVA test, where: **; p < 0.01, ***; p < 0.001. AT-MSCs: Adipose tissue-derived mesenchymal stem cells, EUG: Eugenol.CC BY · PubMed Central
Figure 5 Expression of the proliferating cell nuclear antigen. (A) Representative photos of PCNA staining of hepatic tissues of: (a) normal control rats, (b) fibrotic rats which received CCl4, (c) rats that received CCl4 + AT-MSCs, (d) rats receiving CCl4 + EUG, (e) rats who received CCl4 + AT-MSCs + EUG, (Magnification: x400). (B) Staining intensities were expressed in immuno-reactive score (IRS). Bars represent mean ± SD. Significant difference between groups is analyzed by one-way ANOVA test, where: *; p < 0.05, **; p < 0.01, ***; p < 0.001. AT-MSCs: Adipose tissue-derived mesenchymal stem cells, EUG: Eugenol, PCNA: Proliferating cell nuclear antigen, IRS: Immuno-reactive score.
Figure 5 Expression of the proliferating cell nuclear antigen. (A) Representative photos of PCNA staining of hepatic tissues of: (a) normal control rats, (b) fibrotic rats which received CCl4, (c) rats that received CCl4 + AT-MSCs, (d) rats receiving CCl4 + EUG, (e) rats who received CCl4 + AT-MSCs + EUG, (Magnification: x400). (B) Staining intensities were expressed in immuno-reactive score (IRS). Bars represent mean ± SD. Significant difference between groups is analyzed by one-way ANOVA test, where: *; p < 0.05, **; p < 0.01, ***; p < 0.001. AT-MSCs: Adipose tissue-derived mesenchymal stem cells, EUG: Eugenol, PCNA: Proliferating cell nuclear antigen, IRS: Immuno-reactive score.CC BY · PubMed Central
Figure 6 Expression of Type 1 collagen, α-SMA and TGF-β1 genes. Quantitative real time polymerase chain reaction (RT-PCR) was used to estimate the expression of (A) Type 1 collagen, (B) α-SMA and (C) TGF-β1 genes in hepatic tissues for the different groups. Fold change relative to the expression of normal control group and normalized to the internal control glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was shown. Bars represent mean ± SD. Significant difference between groups is analyzed by one-way ANOVA test, where: **; p < 0.01 and ***; p < 0.001. AT-MSCs: Adipose tissue-derived mesenchymal stem cells, EUG: Eugenol, α-SMA: α-smooth muscle actin, TGF-β1: Transforming growth factor-β, GAPDH: glyceraldehyde 3-phosphate dehydrogenase.
Figure 6 Expression of Type 1 collagen, α-SMA and TGF-β1 genes. Quantitative real time polymerase chain reaction (RT-PCR) was used to estimate the expression of (A) Type 1 collagen, (B) α-SMA and (C) TGF-β1 genes in hepatic tissues for the different groups. Fold change relative to the expression of normal control group and normalized to the internal control glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was shown. Bars represent mean ± SD. Significant difference between groups is analyzed by one-way ANOVA test, where: **; p < 0.01 and ***; p < 0.001. AT-MSCs: Adipose tissue-derived mesenchymal stem cells, EUG: Eugenol, α-SMA: α-smooth muscle actin, TGF-β1: Transforming growth factor-β, GAPDH: glyceraldehyde 3-phosphate dehydrogenase.CC BY · PubMed Central
Figure 7 Expression of α-SMA, TGF-β1 and phospho-Smad3 proteins. (A) Representative immunoprecipitation blots of α-SMA, TGF-β1, Smad3 and P-Smad3 proteins for the different groups. (B) Relative expression of α-SMA and TGF-β1 proteins for the different groups, normalized to β-actin expression. (C) Relative expression of P-Smad3 protein for the different groups, normalized to β-actin and Smad3 proteins expression. Bars represent mean ± SD. Significant difference between groups is analyzed by one-way ANOVA test, where: *; p < 0.05, **; p < 0.01, ***; p < 0.001. AT-MSCs: Adipose tissue-derived mesenchymal stem cells, EUG: Eugenol, α-SMA: α-smooth muscle actin, TGF-β1: Transforming growth factor-β.
Figure 7 Expression of α-SMA, TGF-β1 and phospho-Smad3 proteins. (A) Representative immunoprecipitation blots of α-SMA, TGF-β1, Smad3 and P-Smad3 proteins for the different groups. (B) Relative expression of α-SMA and TGF-β1 proteins for the different groups, normalized to β-actin expression. (C) Relative expression of P-Smad3 protein for the different groups, normalized to β-actin and Smad3 proteins expression. Bars represent mean ± SD. Significant difference between groups is analyzed by one-way ANOVA test, where: *; p < 0.05, **; p < 0.01, ***; p < 0.001. AT-MSCs: Adipose tissue-derived mesenchymal stem cells, EUG: Eugenol, α-SMA: α-smooth muscle actin, TGF-β1: Transforming growth factor-β.CC BY · PubMed Central
Figure 8 Histopathological examination for hepatic tissues. Hematoxylin-eosin (H&E)-stained hepatic sections of: (A) normal control rats, (B) fibrotic rats which received CCl4, (C) rats receiving CCl4 + AT-MSCs, (D) rats who received CCl4 + EUG, (E) rats that received CCl4 + AT-MSCs + EUG, (Magnification: ×100). AT-MSCs: Adipose tissue-derived mesenchymal stem cells, EUG: Eugenol.
Figure 8 Histopathological examination for hepatic tissues. Hematoxylin-eosin (H&E)-stained hepatic sections of: (A) normal control rats, (B) fibrotic rats which received CCl4, (C) rats receiving CCl4 + AT-MSCs, (D) rats who received CCl4 + EUG, (E) rats that received CCl4 + AT-MSCs + EUG, (Magnification: ×100). AT-MSCs: Adipose tissue-derived mesenchymal stem cells, EUG: Eugenol.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 31 references

Cited by

See all 45

Metadata

Authors
Fathy, M., Okabe, M., Saad Eldien, H. M., & Yoshida, T.
Affiliations
  • University of Toyama (JP)
  • Department of Anatomy, College of Medicine, Jouf University, Jouf 74311, Saudi Arabia
Corresponding author
Yoshida, Toshiko
Venue
Molecules
Publisher
MDPI AG
Published
2020-01-15
Volume
25
Issue
2
Pages
348
ISSN
1420-3049 (ISSN-L)
OpenAlex
W3000324902
Cited by
44
References
31
Citations by year
2026: 3 · 2025: 2 · 2024: 10 · 2023: 9 · 2022: 10 · 2021: 7 · 2020: 3
FWCI
3.75
Type
journal article
Language
en
Open access
Locations
  • Molecules (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
Japan Society for the Promotion of Science (20K12642)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Mesenchymal stem cell research
  • Health Sciences › Medicine › Hepatology › Liver physiology and pathology
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Drug-Induced Hepatotoxicity and Protection
Keywords
adipose-derived stem cells, eugenol, antifibrotic activity, liver fibrosis, TGF-β/Smad signaling, Smad3 phosphorylation, carbon tetrachloride-induced liver injury, combination therapy, type I collagen, alpha-smooth muscle actin, inflammatory cytokines, fibrinogen
MeSH terms
Animals, Anti-Infective Agents, Carbon Tetrachloride, Eugenol, Liver Cirrhosis, Male, Signal Transduction, Transforming Growth Factor beta, Rats, Sprague-Dawley, Mesenchymal Stem Cell Transplantation, Rats, Smad Proteins, Mesenchymal Stem Cells

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: AT-MSCs Antifibrotic Activity is Improved by Eugenol through Modulation of TGF-β/Smad Signaling Pathway in Rats. https://app.cochat.ai/papers/10.3390/molecules25020348
The paper
Fathy, M., Okabe, M., Saad Eldien, H. M., & Yoshida, T. (2020). AT-MSCs Antifibrotic Activity is Improved by Eugenol through Modulation of TGF-β/Smad Signaling Pathway in Rats. Molecules. https://doi.org/10.3390/molecules25020348

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.